spaglumic acid
Small moleculeexperimental
N-Acetylaspartylglutamic acid is a peptide neurotransmitter and the third-most-prevalent neurotransmitter in the mammalian nervous system. NAAG consists of N-acetylaspartic acid (NAA) and glutamic acid coupled via a peptide bond. — Wikipedia
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
1
Earliest trial started Oct 1, 2010 (NCT01203540)
Timeline
No events for the selected filters.
Indications
Approved for
Studied for
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
CC(=O)N[C@@H](CC(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)O- Mol. weight
- 304.25 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaN-Acetylaspartylglutamic acid ↗
- ChEMBLCHEMBL2105616 ↗
Also known as
- beta-naag
- n-acetyl-l-β-aspartyl-l-glutamic acid
- n-acetyl-l-β-aspartyl-l-glutamic acid
- spaglumic acid
- spaglumic acid
- spaglumic acid
- spaglumic acid
- spaglumic acid
- spaglumic acid
- spaglumic acid
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01203540 | Phase 4 | Oct 1, 2010 | Laboratoires Thea, Samil Pharmaceutical Co., Ltd. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Laboratoires Thea | For profit | 1 | 1 | 1 | 2010 |
| Samil Pharmaceutical Co., Ltd. | For profit | 1 | 0 | 1 | 2010 |
2 organizations
Page 1 / 1